Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | SSTR3 | P32745 | 2/20 | 0.40 |
| ▸ | MT-CO2 | P00403 | 2/20 | 0.40 |
| ▸ | TOP1 | P11387 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8081000 | 0.86 | CA1 (0.55) | P2RX7MEN1KMT2ALMNAHPGD | |
| SCHEMBL7658512 | 0.85 | P2RX7 (0.54) | P2RX7MEN1KMT2ALMNAHPGD | |
| SCHEMBL7560739 | 0.84 | P2RX7 (0.55) | P2RX7MEN1KMT2ALMNAHPGD | |
| SCHEMBL7552476 | 0.84 | HPGD (0.54) | P2RX7MEN1KMT2AHPGD | |
| SCHEMBL4101685 | 0.84 | MEN1 (0.42) | P2RX7MEN1KMT2ALMNAHPGD | |
| SCHEMBL7554542 | 0.83 | EPHX2 (0.49) | PPARGP2RX7MEN1KMT2ALMNA | |
| SCHEMBL5334659 | 0.83 | CYP4F2 (0.46) | PPARGP2RX7MEN1KMT2ALMNA | |
| SCHEMBL7560196 | 0.82 | MEN1 (0.40) | P2RX7MEN1KMT2ALMNAHPGD | |
| SCHEMBL8080846 | 0.81 | LMNA (0.39) | NPC1RAB9APPARGP2RX7MEN1 | |
| SCHEMBL7592357 | 0.80 | HPGD (0.54) | NPC1RAB9AP2RX7LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010003121-A1 | Novel compounds | ASTRAZENECA UK LIMITED | 2001-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010003121-A1 | Novel compounds | APP, BACE1, CHRNA5 | NPC1 72/4885RAB9A 486/4885PPARG 4053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.